NASHVILLE, Tenn., April 7, 2020 /PRNewswire/ -- Cumberland
Pharmaceuticals Inc. (NASDAQ: CPIX) a specialty
pharmaceutical company, today announced an initiative to increase
availability of Vaprisol® (conivaptan
hydrochloride) injection for treating hyponatremia, associated
with critical care patients during the COVID-19 pandemic. Vaprisol
is an FDA approved treatment for hyponatremia, a potentially
life-threatening condition that can often afflict patients in the
Intensive Care Unit ("ICU").
Cumberland's initiative
includes special supply and financial arrangements, including
favorable pricing and payment terms, for hospitals and clinics to
help ensure timely access to Vaprisol during this healthcare
crisis. For more information regarding this special access, contact
Jim Herman, Cumberland's Senior Vice President National
Accounts at jherman@cumberlandpharma.com.
"It is our hope that this enhanced access to Vaprisol will help
lead to shorter ICU stays and thereby free-up potentially
life-saving ICU beds that could become in short supply during the
COVID-19 pandemic," said A.J. Kazimi, Chief Executive Officer of
Cumberland Pharmaceuticals Inc.
Hyponatremia frequently occurs when the concentration of sodium
in a patient's blood is abnormally low, which can lead to
neurologic dysfunction, decreased mental function and cerebral
edema, among other complications. The condition is particularly
prevalent among ICU patients. On average, over 30 percent of
patients admitted to an ICU have hyponatremia1 and
another 18 percent develop the condition during their ICU
stay2. Several studies have shown that patients with
hyponatremia spend a longer time in the ICU, spend more time on
mechanical ventilators and have increased mortality while in the
ICU3. Vaprisol can help address hyponatremia in the
first 24 hours4.
For more information on Vaprisol, including important dosing and
safety instructions, please see the product website and package
insert at www.vaprisol.com.
References:
- Padni R, Panda BN, Jagati S, et al. Hyponatremia in critically
ill patients. Indian J Crit Care Med. 2014; 18(2):83-7.
- Mahmoud MI, Khalil OA, Afifi WM, et al. Epidemiology and
clinical outcome of ICU-acquired dysnatremia in critically ill
medical patients, a single center study. Life Sci J. 2013;10(2):
415-20.
- Callahan MA, Do HT, Caplan DW, et al. Economic impact of
hyponatremia in hospitalized patients: a retrospective cohort
study. Postgrad Med. 2009;12(2):186-91
- Vaprisol prescribing Information. Cumberland Pharmaceuticals
Inc. 2017.
About Vaprisol®
Vaprisol is an intravenous treatment for hyponatremia used in
the critical care setting. Hyponatremia is an electrolyte
disturbance in which sodium ion concentration in blood plasma is
lower than normal. This can be associated with a variety of
critical care conditions including congestive heart failure, liver
failure, kidney failure, and pneumonia. Vaprisol is a vasopressin
receptor antagonist that raises serum sodium levels and promotes
free water secretion. Vaprisol was approved by the U.S. Food and
Drug Administration in 2005 for euvolemic hyponatremia and in 2007
for hypervolemic hyponatremia. For full prescribing information
visit www.vaprisol.com.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical
company focused on the delivery of high-quality prescription brands
to improve patient care. The Company develops, acquires, and
commercializes brands for the hospital acute care and
gastroenterology market segments. The Company's portfolio of FDA
approved brands includes:
- Acetadote® (acetylcysteine)
Injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) Injection,
for the treatment of pain and fever;
- Kristalose® (lactulose) for Oral
Solution, a prescription laxative, for the treatment of chronic and
acute constipation;
- Omeclamox®-Pak, (omeprazole,
clarithromycin, amoxicillin) for the treatment of Helicobacter
pylori (H. pylori) infection and related duodenal ulcer
disease;
- Vaprisol® (conivaptan) Injection,
to raise serum sodium levels in hospitalized patients with
euvolemic and hypervolemic hyponatremia;
- Vibativ® (telavancin) Injection,
for the treatment of certain serious bacterial infections including
hospital-acquired and ventilator-associated bacterial pneumonia, as
well as complicated skin and skin structure infections;
- RediTrex™ (methotrexate) Injection, for the
treatment of active rheumatoid, juvenile idiopathic and severe
psoriatic arthritis, as well as disabling psoriasis.
For more information on Cumberland's approved products, including full
prescribing information, please visit the individual product
websites, links to which can be found on the Company's website
www.cumberlandpharma.com.
The Company has a series of Phase II clinical programs underway
evaluating its ifetroban product candidates in patients with
cardiomyopathy associated with Duchenne Muscular Dystrophy ("DMD"),
Systemic Sclerosis ("SSc"), and Aspirin-Exacerbated Respiratory
Disease ("AERD"), Hepatorenal Syndrome ("HRS") and Portal
Hypertension ("P.H.").
Forward-Looking Statements
This press release contains forward-looking statements, which
are subject to certain risks and reflect Cumberland's current views on future events
based on what it believes are reasonable assumptions. No assurance
can be given that these events will occur. As with any business,
all phases of Cumberland's
operations are subject to factors outside of its control, and any
one or combination of these factors could materially affect
Cumberland's results of
operations. These factors include market conditions, competition,
an inability of manufacturers to produce Cumberland's products on a timely basis or
failure of manufacturers to comply with regulations applicable to
pharmaceutical manufacturers, maintaining an effective sales and
marketing infrastructure, natural disasters, public health
epidemics, and other events beyond our control, as more fully
discussed in the Company's most recent Form 10-K and subsequent
10-Qs as filed with the SEC. There can be no assurance that results
anticipated by the Company will be realized or that they will have
the expected effects. Readers are cautioned not to place undue
reliance on forward-looking statements, which speak only as of the
date hereof. The Company does not undertake any obligation to
publicly revise these statements to reflect events after the date
hereof.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/to-help-prepare-for-the-covid-19-patient-surge-cumberland-pharmaceuticals-expands-availability-of-vaprisol-to-treat-hyponatremia-in-critical-care-units-301037008.html
SOURCE Cumberland Pharmaceuticals Inc.